Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to see if the Sentinel® Cerebral Protection System may prevent occurrence of stroke during an ablation procedure for atrial fibrillation (AF). The secondary purpose of this study is to study if cognitive function after AF ablation differs between those treated with the Sentinel cerebral protection device and those who do not receive the device.
If assigned to receive the device, the Sentinel® Cerebral Protection System will be placed in your heart at the beginning of your ablation procedure, and then removed along with any collected blood debris upon completion of your procedure. The study team will then call you 30 days after your procedure to assess any neurological events. Your final visit will be 90 days after your procedure to complete a second 30 minute session of cognitive testing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sentinel® Cerebral Protection System Group | Experimental | Sentinel® Cerebral Protection System in patients undergoing AF catheter ablation |
|
| Standard of Care Group | Active Comparator | Standard of care (no cerebral protection device) in patients undergoing AF catheter ablation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sentinel® Cerebral Protection System | Device | A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures. |
| Measure | Description | Time Frame |
|---|---|---|
| Incident of overt and covert CNS injury 7 days post AF ablation | Incidence of overt and covert CNS injury confirmed using physical examination and / or brain imaging during or within 7 days of the AF ablation | 7 days post AF ablation |
| Incident of overt and covert CNS injury 90 days post AF ablation | Incidence of overt and covert CNS injury during or within 90 days of the AF ablation | 90 days post AF ablation |
| Measure | Description | Time Frame |
|---|---|---|
| Change in neurocognitive function score | Montreal cognitive assessment will administered at baseline and 90 days following ablation. Change in cognitive function score will be compared between the groups. The score ranges from 0 to 30 with higher score indicating better cognitive performance. | Baseline, 90 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Anatomy unsuitable for use of Sentinel device:
Cerebrovascular accident or transient ischemic attack within six months
Carotid disease requiring treatment within six weeks
Unable or unwilling to provide informed consent.
Pregnant women
Known history of dementia.
Known hypersensitivity to nickel-titanium.
Presence of MRI non-compatible implanted devices including cardiac implantable electronic devices.
The presence of left atrial thrombus. All patients routinely undergo transesophageal echocardiogram prior to ablation and / or intra-cardiac echocardiogram at the beginning of the ablation procedure to rule out the presence of left atrial thrombus.
Patients with a reversible cause for AF such as hyperthyroidism.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Grace Purkey | Contact | (507) 255-0774 | Purkey.Grace@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Malini Madhavan, MBBS | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Recruiting | Rochester | Minnesota | 55905 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D008279 | Magnetic Resonance Imaging |
| ID | Term |
|---|---|
| D014054 | Tomography |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Randomized study of Sentinel cerebral protection device vs no cerebral protection device in patients undergoing atrial fibrillation ablation.
Not provided
Not provided
Not provided
Not provided
| Magnetic Resonance Imaging | Diagnostic Test | Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation |
|
|
| New cerebral infarcts |
Total number of new cerebral infarcts in the protected territories detected on brain MRI after ablation in the Sentinel device group vs control group |
| day 1 to 7 after atrial fibrillation ablation |